# US 11,077,177 B2 · Universal cancer vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,177 B2
- Document ID: US11077177B2
- Status: Granted
- Kind: B2
- Application number: 15/906,876
- Filed: 2018-02-27
- Published: 2018-09-13
- Granted: 2021-08-03
- Earliest claimed: 2016-02-23
- Applicants: Maurizio Zanetti
- Inventors: Maurizio Zanetti
- Web page: https://patentgrep.com/patent/US11077177B2

## CPC

- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 38/45: Transferases (2)
- A61K 39/015: Hemosporidia antigens, e.g. Plasmodium antigens
- A61K 39/12: Viral antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 40/13: B-cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/4246: {Telomerase or [telomerase reverse transcriptase [TERT]}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/56: Kidney
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18434: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are compositions of matter and methods for treating cancer. The compositions comprise altered human telomerase polypeptides containing T cell epitopes that have been altered to increase immunogenicity. The methods comprise administration of the polypeptides or nucleic acids, such as DNA or RNA encoding the polypeptides, to individuals afflicted with, or at risk of, developing cancer.

## Claims

### Claim 1

An altered human telomerase polypeptide with at least 90% identity to the sequence set forth in SEQ ID NO: 1, wherein the altered human telomerase polypeptide comprises at least five or more amino acid substitutions that are at position R19, L22, R132, L152, D444, K492, E555, L556, T564, R572, R577, D637, L675, E727, R742, T765, R811, L840, G847, T874, L940, K981, V997, or P1020 of telomerase.

### Claim 2 (depends on 1)

The altered human telomerase polypeptide of claim 1, wherein the altered human telomerase polypeptide comprises an insertion of a non-human T cell helper epitope into the polypeptide sequence of the altered human telomerase, wherein the non-human T cell helper epitope binds more than one human class II HLA type.

### Claim 3 (depends on 1)

The polypeptide of claim 1 encoded by a polynucleotide.

### Claim 4 (depends on 3)

The altered human telomerase polynucleotide of claim 3, wherein the polynucleotide comprises ribonucleic acid (RNA).

### Claim 5 (depends on 1)

The altered human telomerase polypeptide of claim 1, wherein at least eight contiguous amino acids of the polypeptide is bound to a cell surface human leukocyte antigen of an antigen presenting cell, wherein the at least eight contiguous amino acids comprise an amino acid substitution of claim 1.

### Claim 6 (depends on 1)

The altered human telomerase polypeptide of claim 1, further comprising an immunological adjuvant.

### Claim 7 (depends on 1)

The altered human telomerase polypeptide of claim 1, wherein the polypeptide comprises at least 95% identity to the sequence set forth in SEQ ID NO: 1.

### Claim 8 (depends on 1)

The altered human telomerase polypeptide of claim 1, wherein the polypeptide comprises at least 98% identity to the sequence set forth in SEQ ID NO: 1.

### Claim 9 (depends on 2)

The altered human telomerase polypeptide of claim 2, wherein the non-human T cell helper epitope comprises any one of SEQ ID NO: 30 to SEQ ID NO: 55.

### Claim 10 (depends on 2)

The altered human telomerase polypeptide of claim 2, wherein the non-human T cell helper epitope comprises SEQ ID NO: 30.

### Claim 11 (depends on 3)

The altered human telomerase polynucleotide of claim 3, wherein the polynucleotide comprises deoxyribonucleic acid (DNA).